This full-day training is the equivalent of 6 hours CPD, and is suitable for those who have an advanced knowledge of the treatment and management of children and young people with an ADHD diagnosis. This Masterclass offers both clinicians and researchers the opportunity to update their knowledge of the evidence-base and its implications for best-practice. This is a unique opportunity to learn from the best-of-the-best in the field of ADHD.
You can book online using the button above or simply download our booking form and email or post it back to us
Learning outcomes and key takeaways:
- Consider whether therapeutic intervention for ADHD depends on scientific progress.
- Understand the role of genetic and environmental factors in the aetiology of ADHD, and the implications for treatment.
- Recognise that ADHD is a neuro-biologically heterogeneous condition, and ask whether it is important to tailor treatments to address different causal profiles in different individuals.
- To be aware of, and critically appraise, available evidence synthesis on the pharmacological and non-pharmacological treatments for ADHD
- To appreciate to which extent current guidelines are based on empirical evidence.
The ‘Masterclass Series’
This CPD training day is part of ACAMH’s ‘Masterclass Series’. The ‘Masterclass Series’ delivers advanced, evidence-based training for those working in CYP mental health, to build upon their skills, knowledge and experience. They are interactive sessions, consisting of a series of lectures delivered by world-renowned experts in the field who focus on the latest research, and the implications for best-practice.
About the day
Neuroscience provides a rational basis for the discovery of new and/or more effective treatments for ADHD. Over the last twenty years our view of ADHD neurobiology has changed considerably, with modern views emphasising its complexity and heterogeneity. This provides a potential platform for personalised therapeutic approaches. Our increasing appreciation of the plastic nature of the brain during sensitive developmental windows highlights the potential value of psychological treatments delivered early in development. There is no evidence, from blind raters, suggesting that non-pharmacological strategies for ADHD are efficacious for ADHD core symptoms. The effect sizes for ADHD drugs from short term trials are amongst the highest not only in psychiatry, but also in general medicine. Network meta-analyses aimed to rank ADHD treatments according to their efficacy/safety have been published or are being conducted.
What the delegates said
“I enjoyed the fact it was a Masterclass. So many courses are so basic it is not possible to relate them to the complexities we see in daily clinical life.” Previous delegate
From a previous ADHD course our delegates said…
- Overall value – 100% rated good or very good
- Knowledge gained can be used in an impactful way – 100% rated good or very good
- Quality of speakers 100% – rated very good
Who should attend
This day would be beneficial to those who work in a clinical or research setting with an advanced understanding of ADHD in children and young people. In particular; consultants, clinical leads, speciality doctors, nurse practitioners, educational psychologists, senior researchers, and those that work with children effected with mental health issues.
About the Speakers
Professor Edmund Sonuga-Barke, Professor of Developmental Psychology and Neuroscience, Department of Child and Adolescent Psychiatry at the IoPPN, Kings College London.
Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King’s College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.
His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders. In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.
Dr Samuele Cortese, MD, PhD, Associate Professor at the University of Southampton and Honorary Consultant with Solent NHS Trust.
Samuele Cortese, MD, PhD, is a child psychiatrist, trained in Italy, France, and in the United States. He is currently an Associate Professor at the University of Southampton and Honorary Consultant with Solent NHS Trust. He is also Adjunct Associate Professor with the New York University (NYU).Dr Cortese’s main research interest are around the epidemiology, neurobiology and treatment of neurodevelopmental disorders, in particular ADHD, as well as on sleep disorders in children and adolescents. He has published more than 120 peer review papers (H index: 39).
Dr Cortese sits on the editorial board of several journals in the field of child mental health, including JCPP, JAACAP, Attention Deficit Hyperactivity Disorders, CNS Drugs, Journal of Child and Adolescent Psychopharmacology and Evidence Based Mental Health. Dr Cortese is a member of the European ADHD Guidelines Group and acts as the ACAMH Branch Liaison Officer.
Platinum Member– £147.00
Gold Member – £168.00
Silver/Bronze Member – £189.00
Publications/Digital – £74.00*
Non-Member – £210.00
*NB there are just 3 tickets left for Publications/Digital Members using a discount voucher